Eosinophilic Chronic Obstructive Pulmonary Disease: Implications for Exacerbations, Readmissions, and Treatment

Affiliations

Comment

Mona T Vashi et al. Am J Respir Crit Care Med. 2019.

. 2019 Jan 1;199(1):110-112.

doi: 10.1164/rccm.201802-0328RR.

¹ Division of Pulmonary and Critical Care, Rush University Medical Center, Chicago, Illinois.

No abstract available

Comment on

Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions.
Couillard S, Larivée P, Courteau J, Vanasse A. Couillard S, et al. Chest. 2017 Feb;151(2):366-373. doi: 10.1016/j.chest.2016.10.003. Epub 2016 Oct 13. Chest. 2017. PMID: 27746201
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC. Pavord ID, et al. N Engl J Med. 2017 Oct 26;377(17):1613-1629. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28893134 Clinical Trial.
Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort.
Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, Devaster JM, Aris E, Clarke SC, Tuck AC, Bourne SC, Wilkinson TMA; AERIS Study Group. Kim VL, et al. Eur Respir J. 2017 Oct 12;50(4):1700853. doi: 10.1183/13993003.00853-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29025891